MEKAWIRE
United States

Remedy Robotics

San Francisco developer of the N1, an AI-enabled robotic system for on-site, remote and autonomous endovascular procedures (investigational).

Remedy Robotics has raised $62M across 1 disclosed round since Nov 16, 2026; the latest round, Series B, was announced on Nov 16, 2026. Data as of Nov 17, 2026.

Headquartered in San Francisco, United States.

Latest from MEKAWIRE

  • Nov 17, 2026
    Remedy Robotics raises $62M Series B led by DCVC for its N1 endovascular robot

    Remedy Robotics, a San Francisco developer of robots for catheter-based stroke and heart procedures, said in a press release dated Nov 16 that it raised $62 million in a Series B round led by DCVC. The company said the money will fund a planned pivotal clinical trial with the University of California, work toward FDA approval for neurovascular intervention and prototype N1 deployments with clinical partners. The N1 is not available for sale or clinical use in any jurisdiction.

    Subject

Related companies